LAS VEGAS—Noom launched its own wearable to enhance its metabolic health platform with activity, sleep and cardiovascular data insights.
The device, called Noom Band, will be bundled into Noom’s existing enterprise partnerships at no additional upfront cost, starting in early 2027. The wearable is also free for Noom Health employer and health plan customers.
The introduction of a wearable is part of Noom’s broader push to build an integrated metabolic health platform combining behavior change, virtual care, diagnostics, medications and continuous health data.
Noom Band is a faceless wrist-worn wearable powered by Sensor Bio,and it will be fully integrated into the Noom app. The device will track heart rate, heart rate variability, SpO2, sleep and activity, with the data feeding directly into Noom’s behavior change platform, executives said.
Noom is providing the wearable to enterprise clients at no additional upfront cost as it sees opportunities to use continuous data on sleep, activity and other physiological signals to keep members engaged and drive better outcomes in the company's weight management and metabolic health programs, Noom CEO Geoff Cook told Fierce Healthcare.
"We are getting outcomes-based payments, so we believe we will have more people hitting their 5% weight loss goals or 10% weight loss goals, if they have the wearable, than if they don't," Cook said in an exclusive interview about the launch of Noom Band.
Integrating a wearable device into Noom’s metabolic health program fills a major data gap, Cook said.
Noom has evolved from a weight loss app into a broader preventive care and clinical health platform. The company's behavior change platform uses psychology, clinical support and structured habit design to help users build long-term lifestyle shifts. The company also offers integrated telehealth services through its Noom Med platform, combining remote clinical care and prescription weight loss medications with its core behavior change app. And, the company has expanded into at-home diagnostics with its Biomarkers Test Kit.
But Noom lacked continuous physiological information, particularly around sleep and activity, Cook said. Less than 10% of members have devices such as the Oura Ring, Whoop, or newer Fitbits, he noted. Continuous physiological data enables Noom to be a more comprehensive healthcare platform.
"This is all about just boosting signal so that we can deliver the right insights, and to do that, we felt we needed to bring a wearable deeper into our program," he said.
Noom is starting with the Noom Band as a wrist-based wearable, and the company is at an “earlier stage exploring ring-based options,” Cook said. "We believe ultimately it’s important to meet people where they are, and both the wrist and the ring form factors have a role to play in generating signal to drive health outcomes, as people have different preferences," he added.
Cook sees chronic care, telehealth, diagnostics and wearable companies increasingly converging as they broaden their capabilities and move into adjacent areas of healthcare.
"Every player in preventive health, which is looking more and more like healthcare generally, is chasing this same holy grail of determining what is going on in a patient or member’s body, and then suggesting a behavioral insight or a pharmaceutical intervention, or ordering a diagnostic test based on that signal," he said.
Noom is making strategic moves to cover all of those capabilities itself.
The company focuses on whole person health that goes beyond nutrition, Cook said, with extensive data and interventions around food and activity but comparatively little insight into sleep. Sleep is an important factor for metabolic health, and the Noom Band gives the company a way to incorporate sleep alongside nutrition, activity and mindset, executives said.
Noom is betting that wearables can improve outcomes for members in its weight loss programs. An analysis of 144,000 Noom Med members taking a GLP-1 medication found that those who used a connected wearable were 34% more likely to lose 20 pounds by the fourth month in the program, according to the company. A separate sleep analysis found that, on average, members on a GLP-1 weight loss drug who used Noom Band slept 90 minutes more per week after only two months, and members who started with a sleep deficit added 150 minutes of sleep per week, the company's data shows.
Studies have shown that chronic sleep restriction or poor quality significantly increases the risk of insulin resistance, obesity and type 2 diabetes.
"Bringing that dimension of health into the program we felt was just critically important," Cook said.
The company decided to build a device from the ground up rather than partner with an existing wearable player so it could own the user experience. "We didn't want to pick a partner where essentially that partner’s app would be competing essentially with the Noom application for this signal interpretation," Cook noted.
Many existing wearables focus on optimizing health and athletic performance, Cody Fair, Noom Health’s chief commercial officer, told Fierce Healthcare. Noom developed Noom Band to capture measurements related to weight management and metabolic health, he noted.
Through the partnership with Sensor Bio, the wearable platform provides the validated sensors and underlying physiological data, while Noom controls how those signals are interpreted and incorporated into interventions. Cook cited SensorBio's research, validation work and focus on device accuracy as key reasons Noom selected Sensor Bio as its partner to develop Noom Band.
By investing in a wearable, Noom also aims to improve member engagement to ultimately drive better outcomes for the members as well as payers and employers, Fair noted.
Members can lose motivation when the number on the scale stops moving. Giving them other measures of progress, including sleep, steps and recovery, provides additional "wins" that could keep them engaged, he said.
Noom also plans to offer the wearable as something that members can "unlock" when they hit early milestones in the program, turning the hardware into an engagement incentive, executives said.
"We didn’t set out to build another wearable – we set out to build the ultimate metabolic health program that drives better health outcomes for members leading to increased ROI for clients," Fair said.
"For employers and health plans, that’s the difference between a fitness perk that gets left in a drawer and a tool built to deliver health outcomes they’re already paying for and that is available to their population at no additional cost, he said.
Expensive wearables can undermine the ROI payers are looking for, Cook noted. "I essentially believe that the devices are a commodity and should effectively be given away. That’s why we're including the wearable at no additional cost to the payer," he said.
Payers and employers also want to see ROI on health programs within a shorter time frame, within 12 to 24 months, Fair added. Providing employers with a program that combines behavior change, wearables and biomarker testing also reduces the number of vendors they have to work with, he added.
Health plans want evidence that daily behavior changes translate into measurable clinical and financial outcomes, such as improvements in blood pressure and A1C, and Noom plans to study whether its wearable can help deliver that ROI over the next year, Fair said.
The Centers for Medicare and Medicaid Services’ ACCESS Model could serve as a proving ground for Noom to demonstrate how the combination of its behavior change program with wearables such as the Noom Band can affect cardiometabolic health.
Noom plans to participate in CMS’ Advancing Chronic Care with Effective Scalable Solutions model under the cardio-kidney-metabolic clinical track, focusing on conditions like obesity, prediabetes and diabetes improvement. ACCESS is a 10-year initiative to integrate tech-enabled care into Medicare.
"That model is an outcomes-aligned payment model. We're excited to bundle the blood pressure cuff, the wearable, along with the Noom program, to have the absolute maximum effect on the outcomes that are being measured, outcomes like A1C, blood pressure and weight," Cook said.
Cook is bullish that wearables will play a bigger role in chronic condition management as sensors are able to generate more sophisticated physiological data and AI gets better at interpreting the data.
"It should be possible, in my view, within years and maybe quicker than that to have the wearable signal itself provide a blood pressure signal that is validated, which would certainly simplify models like the CMS ACCESS model, if you didn't also have to ship a blood pressure cuff," he said. "These less invasive wearables, as they get more powerful, I think, can be transformative to healthcare generally, and I think the CMS ACCESS model is pointing the way to how they would democratize that, and at a relatively low cost to the ultimate payer."